Answers are grounded in this paper and cite their sources.
This prospective longitudinal study of breast cancer survivors (n = 167) examined the association of apolipoprotein ε4 (APOE ε4) genotype with cognition and interactions with chemotherapy or endocrine therapy up to 6 years after treatment. In general, we found no effects of ε4 across timepoints and treatment exposures; post hoc analysis at 3-6 years suggested a trend towards worse cognition in the domains of attention and learning among ε4 carriers exposed to endocrine therapy. Further study is needed.
No takes yet. Share an insight, caveat, or question.
Dyk et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: